Cargando…
Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/ https://www.ncbi.nlm.nih.gov/pubmed/36509285 http://dx.doi.org/10.1172/jci.insight.152761 |
_version_ | 1784849446018744320 |
---|---|
author | Heiduk, Max Plesca, Ioana Glück, Jessica Müller, Luise Digomann, David Reiche, Charlotte von Renesse, Janusz Decker, Rahel Kahlert, Christoph Sommer, Ulrich Aust, Daniela E. Schmitz, Marc Weitz, Jürgen Seifert, Lena Seifert, Adrian M. |
author_facet | Heiduk, Max Plesca, Ioana Glück, Jessica Müller, Luise Digomann, David Reiche, Charlotte von Renesse, Janusz Decker, Rahel Kahlert, Christoph Sommer, Ulrich Aust, Daniela E. Schmitz, Marc Weitz, Jürgen Seifert, Lena Seifert, Adrian M. |
author_sort | Heiduk, Max |
collection | PubMed |
description | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects of neoadjuvant chemotherapy on the cytokine production of tumor-infiltrating T cells are unknown in PDAC. METHODS: We performed multiplex immunofluorescence to investigate T cell infiltration in 91 patients with PDAC. Using flow cytometry, we analyzed tumor and matched blood samples from 71 patients with PDAC and determined the frequencies of T cell subsets and their cytokine profiles. Both cohorts included patients who underwent primary resection and patients who received neoadjuvant chemotherapy followed by surgical resection. RESULTS: In human PDAC, T cells were particularly enriched within the tumor stroma. Neoadjuvant chemotherapy markedly enhanced T cell density within the ductal area of the tumor. Whereas infiltration of cytotoxic CD8(+) T cells was unaffected by neoadjuvant chemotherapy, the frequency of conventional CD4(+) T cells was increased, and the proportion of Tregs was reduced in the pancreatic tumor microenvironment after neoadjuvant treatment. Moreover, neoadjuvant chemotherapy increased the production of proinflammatory cytokines by tumor-infiltrating T cells, with enhanced TNF-α and IL-2 and reduced IL-4 and IL-10 expression. CONCLUSION: Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile. Combinational treatment strategies incorporating immunotherapy in neoadjuvant regimens may unleash more effective antitumor responses and improve prognosis of pancreatic cancer. FUNDING: This work was supported by the Jung Foundation for Science and Research, the Monika Kutzner Foundation, the German Research Foundation (SE2980/5-1), the German Cancer Consortium, and the Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden. |
format | Online Article Text |
id | pubmed-9746809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-97468092022-12-15 Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer Heiduk, Max Plesca, Ioana Glück, Jessica Müller, Luise Digomann, David Reiche, Charlotte von Renesse, Janusz Decker, Rahel Kahlert, Christoph Sommer, Ulrich Aust, Daniela E. Schmitz, Marc Weitz, Jürgen Seifert, Lena Seifert, Adrian M. JCI Insight Clinical Medicine BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects of neoadjuvant chemotherapy on the cytokine production of tumor-infiltrating T cells are unknown in PDAC. METHODS: We performed multiplex immunofluorescence to investigate T cell infiltration in 91 patients with PDAC. Using flow cytometry, we analyzed tumor and matched blood samples from 71 patients with PDAC and determined the frequencies of T cell subsets and their cytokine profiles. Both cohorts included patients who underwent primary resection and patients who received neoadjuvant chemotherapy followed by surgical resection. RESULTS: In human PDAC, T cells were particularly enriched within the tumor stroma. Neoadjuvant chemotherapy markedly enhanced T cell density within the ductal area of the tumor. Whereas infiltration of cytotoxic CD8(+) T cells was unaffected by neoadjuvant chemotherapy, the frequency of conventional CD4(+) T cells was increased, and the proportion of Tregs was reduced in the pancreatic tumor microenvironment after neoadjuvant treatment. Moreover, neoadjuvant chemotherapy increased the production of proinflammatory cytokines by tumor-infiltrating T cells, with enhanced TNF-α and IL-2 and reduced IL-4 and IL-10 expression. CONCLUSION: Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile. Combinational treatment strategies incorporating immunotherapy in neoadjuvant regimens may unleash more effective antitumor responses and improve prognosis of pancreatic cancer. FUNDING: This work was supported by the Jung Foundation for Science and Research, the Monika Kutzner Foundation, the German Research Foundation (SE2980/5-1), the German Cancer Consortium, and the Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden. American Society for Clinical Investigation 2022-11-22 /pmc/articles/PMC9746809/ /pubmed/36509285 http://dx.doi.org/10.1172/jci.insight.152761 Text en © 2022 Heiduk et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Medicine Heiduk, Max Plesca, Ioana Glück, Jessica Müller, Luise Digomann, David Reiche, Charlotte von Renesse, Janusz Decker, Rahel Kahlert, Christoph Sommer, Ulrich Aust, Daniela E. Schmitz, Marc Weitz, Jürgen Seifert, Lena Seifert, Adrian M. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title | Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title_full | Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title_fullStr | Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title_full_unstemmed | Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title_short | Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer |
title_sort | neoadjuvant chemotherapy drives intratumoral t cells toward a proinflammatory profile in pancreatic cancer |
topic | Clinical Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/ https://www.ncbi.nlm.nih.gov/pubmed/36509285 http://dx.doi.org/10.1172/jci.insight.152761 |
work_keys_str_mv | AT heidukmax neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT plescaioana neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT gluckjessica neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT mullerluise neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT digomanndavid neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT reichecharlotte neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT vonrenessejanusz neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT deckerrahel neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT kahlertchristoph neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT sommerulrich neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT austdanielae neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT schmitzmarc neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT weitzjurgen neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT seifertlena neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer AT seifertadrianm neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer |